US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Synaptogenix Inc (SNPX)
Synaptogenix Inc (SNPX) ニュース

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SNPX

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	06 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNPX	Synaptogenix Inc
2024/05/07	22 : 00	PR Newswire (US)	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery	NASDAQ:SNPX	Synaptogenix Inc
2024/04/24	22 : 15	PR Newswire (US)	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	NASDAQ:SNPX	Synaptogenix Inc
2024/04/09	22 : 15	PR Newswire (US)	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	NASDAQ:SNPX	Synaptogenix Inc
2024/04/03	21 : 00	PR Newswire (US)	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	NASDAQ:SNPX	Synaptogenix Inc
2024/02/07	00 : 16	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SNPX	Synaptogenix Inc
2023/12/22	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNPX	Synaptogenix Inc
2023/12/19	23 : 00	PR Newswire (US)	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	NASDAQ:SNPX	Synaptogenix Inc
2023/12/06	23 : 00	PR Newswire (US)	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	NASDAQ:SNPX	Synaptogenix Inc
2023/11/15	07 : 05	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:SNPX	Synaptogenix Inc
2023/11/14	07 : 00	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SNPX	Synaptogenix Inc
2023/11/07	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNPX	Synaptogenix Inc
2023/11/04	06 : 00	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SNPX	Synaptogenix Inc
2023/11/02	22 : 00	PR Newswire (US)	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology	NASDAQ:SNPX	Synaptogenix Inc
2023/09/26	22 : 00	PR Newswire (US)	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease	NASDAQ:SNPX	Synaptogenix Inc
2023/09/23	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNPX	Synaptogenix Inc
2023/09/07	22 : 00	PR Newswire (US)	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study	NASDAQ:SNPX	Synaptogenix Inc
2023/08/15	06 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNPX	Synaptogenix Inc
2023/07/19	22 : 00	PR Newswire (US)	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	NASDAQ:SNPX	Synaptogenix Inc
2023/07/19	21 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNPX	Synaptogenix Inc
2023/07/13	22 : 00	PR Newswire (US)	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience	NASDAQ:SNPX	Synaptogenix Inc
2023/06/23	06 : 15	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SNPX	Synaptogenix Inc
2023/05/16	05 : 51	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:SNPX	Synaptogenix Inc
2023/04/29	06 : 08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SNPX	Synaptogenix Inc
2023/04/15	06 : 01	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SNPX	Synaptogenix Inc
2023/04/01	05 : 23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SNPX	Synaptogenix Inc
2023/04/01	05 : 23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SNPX	Synaptogenix Inc
2023/04/01	05 : 22	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SNPX	Synaptogenix Inc
2023/04/01	05 : 21	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SNPX	Synaptogenix Inc
2023/03/22	06 : 24	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:SNPX	Synaptogenix Inc

Showing the most relevant articles for your search:NASDAQ:SNPX

1 2 3 4 次へ >>

Charter Communications

Mesbon China Nylon

Caisse depots et Consign...

CSNAG131 Ex:12,44

Megalith Financial Acqui...

BNP Paribas Issuance

Tokamak Network Token

Deutsche Bank Luxembourg

American Water Works

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約